Selpercatinib Gets Traditional FDA Approval for RET Fusion Solid Tumors

In brief

On July 14, 2026, the FDA granted traditional approval to selpercatinib, marketed as Retevmo, for adults and children age 2 and older with advanced or metastatic solid tumors that have a RET gene fusion.

The approval is tumor-agnostic. That means the target is a tumor feature - the RET fusion - rather than only one organ-based cancer type. The FDA notice applies after prior systemic treatment or when there are no satisfactory alternative treatment options.

What happened

Selpercatinib was already used for some cancers with RET alterations. The July 2026 action converted its RET fusion-positive solid tumor indication from accelerated approval to traditional approval.

Accelerated approval can allow earlier access when a drug shows a strong early signal, often tumor response, in a serious disease setting. Traditional approval means the FDA has accepted additional evidence supporting the benefit-risk assessment for the approved indication.

The FDA notice describes evidence from people with RET fusion-positive solid tumors across several tumor types. The key point for readers is not that all cancers are treated the same way. It is that some cancers from different organs can share a molecular driver that makes a targeted therapy relevant.

Why RET fusions matter

Genes are instructions cells use to make proteins. A fusion happens when part of one gene joins with part of another gene. Some gene fusions can act like a stuck accelerator for cancer growth.

RET is one of those cancer-related genes. If a tumor has a RET fusion, a RET inhibitor such as selpercatinib may be considered in the right clinical setting. But the fusion has to be found first. That is why biomarker testing can be central to treatment decisions for some advanced cancers.

What this does not mean

• It does not mean selpercatinib treats all solid tumors.
• It does not mean a person should take the drug without a confirmed RET fusion and an oncology team recommending it.
• It does not mean tumor location no longer matters. The cancer type, stage, prior treatments, symptoms, and other tumor features still matter.
• It does not mean every RET alteration is the same. A RET fusion is different from some other RET changes.
• It does not remove the need to understand side effects, monitoring, fertility considerations, drug interactions, and insurance coverage.

Why patients may hear more about this

Tumor-agnostic approvals are easier to misunderstand than organ-specific approvals. A headline may say "solid tumors," but the actual indication is narrower: the tumor must have the specific biomarker, and the patient's treatment history must fit the label.

For people with advanced cancer, this kind of approval can make biomarker testing feel more practical. It gives clinicians another reason to ask whether the tumor has been tested for actionable changes.

Questions to ask a healthcare team

• Has my tumor been tested for RET fusions or other actionable biomarkers?
• If testing was done earlier, should it be repeated or expanded?
• Does this FDA approval apply to my cancer type and treatment history?
• What benefits and risks were seen in the studies?
• Are there clinical trials that would be relevant to my biomarker results?

Sources

This article was written from the sources below, which were checked on July 18, 2026.

• U.S. Food and Drug Administration. "FDA approves selpercatinib for RET fusion-positive solid tumors." Published July 14, 2026.
• U.S. Food and Drug Administration. Oncology/Cancer/Hematologic Malignancies Approval Notifications.
• National Cancer Institute background pages on targeted therapy, biomarker testing, and tumor-agnostic therapy.

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels unsafe or unclear? Report it here - we log and act on material corrections.